Alnylam has crossed into profitable commercial-stage biotech, powered by AMVUTTRA and a fast-growing TTR franchise. Valuation is rich, but the company’s revenue growth, cash generation, and pipeline support a Buy rating.
Alnylam Pharmaceuticals (ALNY) has moved from a loss-making biotechnology developer to a profitable commercial-stage company, with AMVUTTRA and the broader TTR franchise now driving the investment case. The company generated $3.71B of revenue in 2025, posted $501.6M of operating income, and produced $465.4M of free cash flow. TTM revenue stands at $4.80B, with a 16.1% net margin and 66.9% year-over-year revenue growth.
The core growth engine remains powerful. Q2 2026 TTR revenue reached $1.03B, up 89% year over year and 13% from Q1. AMVUTTRA revenue exceeded $1B in a single quarter for the first time, only 15 months after its ATTR cardiomyopathy launch. The product benefits from quarterly dosing, broad access, adherence above 90%, and a clinical profile that supports first-line use.
The risk is valuation and concentration. Alnylam trades at 41.2x trailing earnings and 26.4x forward earnings, while AMVUTTRA supplies the majority of the growth narrative. Management lowered 2026 TTR guidance by $200M at the midpoint after early second-line demand normalized. That reset makes execution more credible, but it also shows how quickly launch assumptions can change.
For a moderate-risk investor with a medium-term horizon, ALNY merits a Buy rating rather than a speculative Strong Buy. The balance sheet, cash generation, platform leadership, and pipeline support durable value creation, while the current earnings multiple and recent guidance reduction argue for disciplined position sizing.
Founded in 2002 and headquartered in Cambridge, Massachusetts, Alnylam is a biotechnology company focused on RNA interference, or RNAi, therapeutics. The company employs approximately 2,500 people and trades on the NASDAQ under ALNY. Its medicines use small interfering RNA to silence messenger RNA before disease-causing proteins are produced.
The company’s Alnylam 2030 strategy has three pillars: global TTR leadership, sustainable innovation beyond TTR, and disciplined scaling. Management targets revenue growth of at least 25% annually through 2030 and a non-GAAP operating margin near 30%. The company also targets two or more new transformative medicines beyond TTR and expansion into 10 tissue types.
This is no longer a platform awaiting commercial proof. In 2025, Alnylam delivered its first full year of operating income and positive net income, while its approved and partnered medicines created multiple revenue channels. The market is now valuing the company as a growth biopharmaceutical business rather than as a traditional development-stage biotech.
The TTR franchise is the economic center of Alnylam. Global TTR revenue reached $1.03B in Q2 2026, compared with $910M in Q1 2026. U.S. TTR revenue rose 114% year over year and 15% sequentially, while revenue outside the U.S. increased 31% year over year and 7% sequentially.
The rare disease portfolio generated $142M of net revenue in Q2, up 11% year over year. GIVLAARI revenue grew alongside a 16% increase in global patients on therapy in Q1 2026, while OXLUMO benefited from a 21% increase in global patients on therapy. These products are smaller than AMVUTTRA, but they add recurring revenue and demonstrate the commercial reach of Alnylam’s GalNAc platform.
Partner revenue adds another layer. Q2 collaboration revenue was $47M, down 23% year over year because of lower Regeneron revenue recognition. Royalty revenue increased 79% to $72M, driven by higher Leqvio sales at Novartis. The mix shows both the strength and variability of partnered revenue: royalties can grow rapidly, while collaboration revenue can move with clinical activity and accounting timing.
The segment structure is therefore asymmetrical. TTR provides the dominant growth and profit engine, rare disease products provide a smaller recurring base, and collaborations provide pipeline leverage and royalty optionality. That structure supports operating leverage, but it also makes AMVUTTRA execution central to the entire equity story.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
AMVUTTRA is Alnylam’s flagship product and the principal driver of its valuation. The FDA approved AMVUTTRA for ATTR cardiomyopathy in March 2025 after its earlier approval for hereditary ATTR polyneuropathy. The European Commission approved the cardiomyopathy indication in June 2025, and approvals also extend to Japan, the United Kingdom, Canada, and Brazil.
The commercial evidence is substantial. AMVUTTRA generated more than $1B of revenue in Q2 2026, while global TTR revenue rose 89% year over year. Approximately 80% of new treatment initiations are now first-line starts. Among prescribers already using AMVUTTRA, the product represents more than 50% of new patient starts, and Alnylam added more than 1,700 prescribers from the ATTR cardiomyopathy launch through the end of Q2.
HELIOS-B is the clinical foundation. Management reported that AMVUTTRA met 10 out of 10 endpoints, with reductions of nearly 40% over 48 months across all-cause mortality and cardiovascular events. Treatment effects were preserved with or without background stabilizers, while the product’s quarterly, health-care-provider-administered dosing supports adherence above 90%.
The key commercial adjustment came in 2026. Early second-line demand benefited from pent-up demand among patients moving off stabilizer therapy. That growth later normalized, prompting management to reduce full-year TTR revenue guidance to $4.2B-$4.5B from the original range of $4.4B-$4.7B. The revised range still represents 75% year-over-year growth at the company’s stated outlook.
The product’s long-term runway remains tied to first-line adoption. Management estimates that approximately 80% of ATTR cardiomyopathy patients remain untreated, and the company is investing in diagnosis initiatives with Viz AI, Komodo Health, the American Heart Association, and a large California health system. Those programs address the practical bottleneck in rare disease markets: finding patients before treatment choice becomes relevant.
Alnylam’s competitive advantage begins with delivery. Its GalNAc conjugate technology enables subcutaneous delivery of liver-directed RNAi medicines, while its lipid nanoparticle approach supports systemic delivery. The ESC and ESC+ platforms are designed to improve potency, durability, specificity, and dosing convenience.
The next platform step is IKARIA. Preliminary Phase 1 data for nucresiran showed more than 90% mean TTR reduction at Day 15, a 96% peak mean reduction at Day 29, and more than 90% mean reduction sustained through Day 180 after a single dose. Alnylam expects nucresiran to deliver more than 95% knockdown with two doses per year.
Alnylam is also extending RNAi beyond the liver. Its C16 conjugate technology is being used in mivelsiran for cerebral amyloid angiopathy and Alzheimer’s disease, while ALN-HTT02 targets Huntington’s disease. The company is developing programs in cardiovascular disease, obesity, metabolic disease, bleeding disorders, and neurodegeneration.
The pipeline includes Phase 3 programs for nucresiran in ATTR polyneuropathy and ATTR cardiomyopathy, zilebesiran in hypertension, and collaborator-led cemdisiran programs. Phase 2 programs include mivelsiran, ALN-6400, and ALN-ANG3. ALN-2232 entered Phase 1 as an adipose-directed RNAi program targeting ACVR1C for obesity and weight management.
The main competitive advantage is not one molecule. It is the combination of delivery chemistry, human-genetics research, clinical experience, regulatory knowledge, and commercial infrastructure. Six approved medicines provide a stronger validation record than most RNAi peers, although each new tissue type still carries clinical and technical risk.
Alnylam’s operating model combines internal discovery and development with commercial partnerships. The company directly supports AMVUTTRA, ONPATTRO, GIVLAARI, and OXLUMO, while Novartis and Sanofi commercialize Leqvio and Qfitlia. BeOne has exclusive commercialization and distribution rights for AMVUTTRA in Mainland China and Macau, subject to marketing authorization.
The Q2 2026 cost structure reflects an expanding clinical and commercial footprint. Non-GAAP R&D expense increased 38% year over year to $377M, driven by three Phase 3 studies and additional investment in bleeding disorders, Huntington’s disease, and cerebral amyloid angiopathy. Non-GAAP SG&A increased 14% to $297M, primarily because of the AMVUTTRA cardiomyopathy launch.
Manufacturing efficiency is becoming more important as quarterly AMVUTTRA demand exceeds $1B. Alnylam has highlighted an enzymatic ligation-based RNAi manufacturing platform intended to improve efficiency and scalability. If the platform performs as planned, it can support volume growth and reinforce the company’s gross-margin profile.
Commercial execution also depends on patient identification, reimbursement, specialty distribution, and provider training. Management reported broad access, strong pull-through, and no meaningful reimbursement headwinds after five quarters of the ATTR cardiomyopathy launch. Outside the U.S., TTR growth continued in Japan, the United Kingdom, and Germany despite pricing pressure from new cardiomyopathy launches.
ATTR amyloidosis gives Alnylam a large rare-disease opportunity by specialty-pharma standards. Alnylam estimates that ATTR cardiomyopathy affects more than 300,000 people worldwide, while hereditary ATTR polyneuropathy affects fewer than 30,000. The company’s estimate that approximately 80% of ATTR cardiomyopathy patients remain untreated creates a sizable diagnosis and adoption runway.
The broader RNAi therapeutics market is estimated at $4.2B in 2025 and $6.8B in 2026 by one industry forecast. A separate estimate places the RNAi technology market at $3.95B in 2026 and $8.26B in 2032. These estimates vary by market definition, but both point to a growing commercial setting for companies with validated delivery platforms.
Alnylam is also targeting larger markets. Zilebesiran is in the ZENITH Phase 3 cardiovascular outcomes trial for hypertension, while ALN-2232 addresses obesity and weight management. These programs expand the potential customer base beyond ultra-rare diseases, although their ultimate value depends on clinical results, regulatory outcomes, and commercial positioning.
Market growth is not purely a function of disease prevalence. ATTR requires improved diagnosis, cardiology adoption, reimbursement support, and evidence that changes treatment behavior. Alnylam’s investments in health-system screening and digital diagnosis directly address those adoption factors.
Like what you're reading?
Get full access to AI-powered research reports, market analysis, and portfolio tools.
The immediate customers for AMVUTTRA are specialist physicians, health systems, specialty pharmacies, and payers. Patients typically enter the treatment pathway through cardiology, neurology, or rare-disease practices. Because AMVUTTRA is administered quarterly by a health-care provider, provider capacity and treatment-site access influence the commercial experience.
The product’s customer value proposition rests on three measurable attributes: clinical outcomes, dosing convenience, and adherence. HELIOS-B produced reductions of nearly 40% across all-cause mortality and cardiovascular events over 48 months. Quarterly administration reduces the burden of frequent self-dosing, while reported adherence exceeds 90%.
Prescriber behavior is moving in Alnylam’s favor. AMVUTTRA represents more than 50% of new patient starts among physicians who already use it, and more than 1,700 new prescribers joined the TTR cardiomyopathy network through Q2. Management estimates that only about one-third of the expanding TTR prescriber pool has experience with AMVUTTRA, leaving room for broader adoption.
The customer base for GIVLAARI and OXLUMO is narrower but similarly specialist-driven. In Q1 2026, the number of global patients on therapy grew 16% for GIVLAARI and 21% for OXLUMO. That patient growth supports the durability of Alnylam’s rare-disease revenue outside TTR.
Alnylam competes against direct RNAi developers such as Arrowhead Pharmaceuticals, Silence Therapeutics, Wave Life Sciences, and smaller platform companies. It also competes against antisense, small-molecule, gene-therapy, CRISPR, and other genetic-medicine approaches. Delivery, durability, safety, dosing frequency, and clinical outcomes determine commercial leadership more than the RNAi label alone.
In ATTR, the competitive set includes stabilizers such as tafamidis and antisense programs from Ionis Pharmaceuticals and AstraZeneca. Management cited the negative top-line outcome from the CARDIO-TTRansform study of eplontersen as a favorable development for AMVUTTRA’s competitive position. Tafamidis is expected to retain U.S. exclusivity until 2031, extending the period before generic stabilizer competition.
AMVUTTRA’s distinction is its combination of ATTR cardiomyopathy and hereditary ATTR polyneuropathy approval in the U.S., quarterly dosing, and outcome data from HELIOS-B. Management also argues that rapid and deep TTR knockdown separates RNAi from antisense approaches. That argument is supported by Alnylam’s own approved-product history, although nucresiran’s future clinical value remains tied to the TRITON program.
The company’s platform breadth is a second competitive layer. Leqvio and Qfitlia provide partnered validation outside Alnylam’s direct commercial portfolio, while collaborations with Roche, Regeneron, Sanofi, Novartis, PeptiDream, and Ionis extend development reach. The main threat is that a rival platform produces superior delivery or efficacy in a larger indication.
The most relevant macro forces for ALNY are health-care budgets, reimbursement policy, drug pricing, currency movements, and regulatory execution. Q2 international TTR revenue grew 31% year over year despite pricing headwinds from cardiomyopathy launches in several countries. That result shows strong volume growth, but it also confirms that international expansion does not translate into revenue growth on a uniform price basis.
Regulatory breadth is an advantage and a source of operating complexity. AMVUTTRA has cardiomyopathy approvals in the U.S., European Union, Japan, the United Kingdom, Canada, and Brazil. Leqvio was registered in 108 countries and commercially available in 89 countries at the end of 2025. Each additional market expands reach while adding local pricing, distribution, and compliance requirements.
The FDA’s 2026 actions supporting faster early- and late-stage development for innovative therapies are constructive for platform companies with rare-disease experience. Alnylam’s six approved medicines and long history of RNAi development position it to use those pathways more effectively than a first-time sponsor.
Geographic diversification also reduces dependence on the U.S. market, but it does not remove policy risk. Germany created pricing pressure during its cardiomyopathy launch, and changes in U.S. inventory days on hand reduced reported TTR growth in Q2. These factors make quarterly revenue timing less predictable than underlying patient demand.
Alnylam generated $465.4M of free cash flow in 2025 and ended the period with a stronger commercial profile after posting $501.6M of operating income.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →TTM revenue reached $4.80B with a 16.1% net margin, while 2025 revenue totaled $3.71B and operating income turned positive for the first full year.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Management still targets at least 25% annual revenue growth through 2030 and a non-GAAP operating margin near 30%, even after trimming 2026 TTR guidance by $200M at the midpoint.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →ALNY trades at 41.2x trailing earnings and 26.4x forward earnings, a premium that reflects AMVUTTRA’s momentum but leaves less room for execution missteps.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →A $270 fair value sits between the report’s $220 Buy level and $330 Sell level, matching a B+ overall grade and a Buy recommendation.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Alnylam has earned its place among the leading commercial RNAi companies. Six approved medicines, $3.71B of 2025 revenue, positive operating income, positive free cash flow, and $3.3B of cash, cash equivalents, and marketable securities give the business a stronger foundation than its earlier development-stage history suggests.
AMVUTTRA is the decisive asset. Its Q2 revenue, clinical outcomes, adherence, prescriber growth, and first-line momentum support continued TTR expansion. The normalized second-line demand that forced a guidance reduction is a useful reminder that even excellent launches have a settling period. Markets reward durable demand, not the first burst of demand.
The medium-term opportunity is attractive, but the valuation already recognizes much of the company’s progress. The Buy rating therefore depends on disciplined entry and a willingness to tolerate clinical volatility. At $242.77, ALNY sits below our fair value estimate of $270, with upside supported by TTR execution and pipeline optionality, but the position should remain sized for the risks inherent in a concentrated biotechnology growth story.
Get AI-powered research reports, daily market intelligence, and a personal analyst in your pocket.
Get Full Access →Not ready to subscribe? ·
Cancel anytime
Alnylam Pharmaceuticals, Inc. (ALNY) rises 8.6% as investors react to new ATTR-CM data presented at ESC Congress 2026, with Amvuttra at the center of the move. Strong volume suggests active repricing, while valuation and recent earnings results keep the rally in context.
Alnylam Pharmaceuticals, Inc. (ALNY) tumbles in extended-hours trading ahead of its July 30 Q2 earnings report. The move appears tied to event-driven positioning and profit-taking rather than a new FDA, clinical, or partnership setback, even as the company’s recent revenue and operating income trends remain strong.
Alnylam just got the kind of competitive win biotech investors rarely get handed this cleanly: a rival late-stage ATTR-CM miss after AMVUTTRA already secured the label and commercial traction. With revenue up 65.2% year over year and AMVUTTRA driving more than $1 billion in quarterly product revenue, the stock still looks like the clearest winner in a narrowing field.